Evotec OAI Signs Medicinal Chemistry Agreement with Axxima Pharmaceuticals
Under the terms of the drug discovery contract Evotec OAI will apply its integrated medicinal chemistry platform to optimise initial screening hits already identified by Axxima and rapidly progress them towards novel clinical candidates for clinical trials. Financial details of the collaboration were not disclosed.
"Signing this contract with Axxima is a further strong validation of the quality of our integrated medicinal chemistry offering," said Jörn Aldag, President and Chief Executive Officer of Evotec OAI. "We are delighted that Axxima chose us to support them in building strong intellectual property around one of their anti-infective targets."
"The chemistry expertise provided by Evotec OAI ideally complements our in-house medicinal chemistry programs," said Dr. Gerhard Müller, Chief Scientific Officer of Axxima. "The professionalism of their integrated medicinal chemistry platform qualifies Evotec OAI as an ideal long-term drug discovery partner to support us in progressing selected projects into promising clinical drug candidates."
Most read news
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.